Inquiry
Form loading...

AML 1A 144689-93-0 Treating hypertension

IUPAC Name: ethyl 5-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-4-carboxylate
Molecular Weight: 240.3
Molecular Formula: C12H20N2O3
Quality Standard: In House

    Product Specification

    Appearance:

    Pale-yellow to off-white powder

    Identification:

    Retention time of the sample conforms tothat of the reference standard

    Water:

    Not more than 1.0%

    Residue on ignition:

    Not more than 0.50%

    Melting point:

    Between 100.0℃ and 107.0℃

    Purity and relatedsubstances:

    Impurity A NMT 0.50%、Impurity B NMT 0.50%、Impurity C NMT O.30%、Impurity D NMT 0.10%、Impurity E NMT 0.10%、Impurity F NMT 0.10%、Other single impurities NMT 0.50%

    Purity:

    NLT 99.00%

    description1

    PRODUCT DESCRIPTION

    An appropriate activation of the renin-angiotensin-aldosterone system (RAAS) plays a central role in the onset and progression of important diseases such as hypertension, heart failure, atherosclerosis, and diabetic nephropathy. Our understanding of this pathogenesis is constantly improving. Angiotensin II receptor AT1 antagonists (ARBs) have become increasingly widely used in clinical practice in recent years. AnML 1A is an intermediate of olmesartan, a type of angiotensin II receptor antagonist. It is used as an antihypertensive medication.

    Angiotensin II (Ang II) receptor (AT1) blocker omesartan is a non-peptide. Omesartan does not produce the rash, angioneurotic edema, or dry cough that are connected to angiotensin-converting enzyme inhibitors (ACEIs). Its potent, long-lasting antihypertensive impact is accompanied by fewer side effects. An essential component of the RAAS, Ang II narrows blood vessels, promotes the production of aldosterone, pumps blood through the heart, and improves renal sodium absorption. By specifically preventing Aug III from binding to AT1 receptors in vascular smooth muscle, omesartan counteracts the effects of Ang III and prevents the negative feedback control of renin secretion, which raises levels of circulating Ang III and plasma renin activity. Omesartan's ability to effectively treat hypertension is unaffected by this, though.